Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ALW-II-41-27 |
Synonyms | |
Therapy Description |
ALW-II-41-27 is a small molecule that inhibits EPHA2 and RET, leading to decreased tumor cell proliferation and viability (PMID: 24713656, PMID: 26046350, PMID: 32848131). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ALW-II-41-27 | RET Inhibitor 53 | ALW-II-41-27 is a small molecule that inhibits EPHA2 and RET, leading to decreased tumor cell proliferation and viability (PMID: 24713656, PMID: 26046350, PMID: 32848131). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET C634W | medullary thyroid carcinoma | sensitive | ALW-II-41-27 | Preclinical - Cell culture | Actionable | In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thyroid carcinoma cells harboring RET C634W in culture (PMID: 26046350). | 26046350 |
RET C634Y | Advanced Solid Tumor | sensitive | ALW-II-41-27 | Preclinical - Cell culture | Actionable | In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET C634Y in culture (PMID: 26046350). | 26046350 |
RET M918T | medullary thyroid carcinoma | sensitive | ALW-II-41-27 | Preclinical - Cell culture | Actionable | In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling and reduced proliferation of medullary thryoid carcinoma cells harboring RET M918T in culture (PMID: 26046350). | 26046350 |
RET M918T | Advanced Solid Tumor | sensitive | ALW-II-41-27 | Preclinical - Cell culture | Actionable | In a preclinical study, ALW-II-41-27 inhibited RET phosphorylation and downstream signaling, reduced proliferation of transformed cells expressing RET M918T in culture (PMID: 26046350). | 26046350 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|